SCHEMBL19973896

SCHEMBL19973896

O=C1CCOc2c1c(F)cc(F)c2C(=O)Nc1ccc(F)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.47
RAB9A P51151 7/20 0.44
NPC1 O15118 6/20 0.44
LMNA P02545 2/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
TP53 P04637 4/20 0.43
ALDH1A1 P00352 1/20 0.42
HTT P42858 2/20 0.41
TSHR P16473 1/20 0.41
ENPP2 Q13822 1/20 0.39
POLB P06746 2/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19973431 0.84 MAOB (0.48) MAOBRAB9ANPC1LMNACASP3
SCHEMBL19973962 0.84 MAOB (0.48) MAOBRAB9ANPC1LMNACASP3
SCHEMBL19973892 0.78 MAOB (0.45) MAOBRAB9ANPC1LMNACASP3
SCHEMBL19973436 0.78 NPC1 (0.49) MAOBRAB9ANPC1LMNACASP3
SCHEMBL19973903 0.75 TP53 (0.54) MAOBRAB9ANPC1LMNACASP3
SCHEMBL19973449 0.74 FADS1 (0.49) RAB9ANPC1LMNASMN1; SMN2ALDH1A1
SCHEMBL19973426 0.74 NPSR1 (0.52) RAB9ANPC1LMNASMN1; SMN2TP53
Hydrochloric Acid SCHEMBL19973457 0.74 MAOB (0.45) MAOBRAB9ANPC1LMNACASP3
Hydrochloric Acid SCHEMBL19973458 0.74 MAOB (0.45) MAOBRAB9ANPC1LMNACASP3
SCHEMBL19973491 0.72 MAOB (0.43) MAOBRAB9ANPC1LMNACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US claimed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US claimed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO claimed
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS MAOB 1792/4885RAB9A 1393/4885NPC1 983/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS MAOB 1792/4885RAB9A 1393/4885NPC1 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.